Abstract: Provided herein are compositions comprising a first compound having the structure of first Formula Ia, wherein the first compound comprises a first therapeutic agent having the configuration of [diacid]-[linker]-[an amylin analog], in which the amylin analog has the amino acid sequence of SEQ ID NO: 20, with a proviso that the amino acid sequence comprises one or more of the following amino acid substitutions: N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof, and the first compound has an anion: cation molar ratio of from about 1:1 to about 1:3, and a second compound having the structure of second Formula Ia, wherein the second compound comprises a second therapeutic agent having the sequence of SEQ ID NO: 35, and the second compound has an anion: cation molar ratio of from about 1:1 to about 1:7, and methods of using thereof for the treatment of metabolic diseases or disorders, including type 1 diabetes, type 2 diabetes, obesity, overweight, and nonalcoholic steatohepatitis, and for reducing we

Abstract: Embodiments described herein relate to systems and methods for automation rule creation for collaboration platforms. A natural language user input may be input to a centralized automation rule service that creates prompts for a generative output service to automatically create an automation rule understandable to one or more collaboration platforms of a system. A trigger-selection prompt, component-selection prompt, and rule-selection prompt are generated by the system and provided to the generative output engine. An automation rule can then be identified from the generative response, verified, and used in the system for the one or more collaboration platforms. In some cases, the automation rule creation from natural language input may reduce the burden on a user to craft and manage automation rules in a collaboration platform.

Abstract: Provided herein are compounds having the structure of Formula I, wherein the compounds comprise a therapeutic agent having the configuration of [diacid]-[linker]-[an amylin analog], in which the amylin analog has the amino acid sequence of SEQ ID NO: 20, with a proviso that the amino acid sequence comprises one or more of the following amino acid substitutions: N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof, and the compounds have an anion: cation molar ratio of from about 1:1 to about 1:3, and methods of using thereof for the treatment of metabolic diseases or disorders, including type 1 diabetes, type 2 diabetes, obesity, overweight, and nonalcoholic steatohepatitis, and for reducing weight in a subject in need thereof.

Abstract: Apparatuses, methods, and systems are disclosed for Type-II port-selection codebook generation. One apparatus includes a processor and a transceiver that receives a set of CSI-RS. The processor identifies a set of CSI-RS ports based on the set of CSI-RS. The processor selects a subset of CSI-RS ports from the identified set of CSI-RS ports based on a free selection of the respective CSI-RS ports from the identified CSI-RS ports. The processor generates, based on the set of CSI-RSs, at least one amplitude coefficient indicator and at least one phase coefficient indicator for each selected CSI-RS port generates a CSI report comprising a Type-II port-selection codebook corresponding to the generated coefficients and the subset of CSI-RS ports.

Abstract: Apparatuses, methods, and systems are disclosed for channel state information report coefficients. One method (700) includes receiving (702), at a user equipment, a set of reference signals. The method (700) includes identifying (704) a set of ports based on the set of reference signals. The method (700) includes selecting (706) a subset of ports from the set of ports. The method (700) includes computing (708) a subset of coefficients corresponding to a set of indices for each reference signal in the set of reference signals. The method (700) includes generating (710) a channel state information report comprising the subset of coefficients corresponding to the set of indices for each port in the subset of ports.

Abstract: Apparatuses, methods, and systems are disclosed for preparing channel state information (CSI). One apparatus includes a processor and a memory with instructions executable by the processor to cause the apparatus to cause a base station to receive, from a user equipment (UE), CSI based on a CSI codebook which includes a plurality of precoding matrices; decode a codeword based on the CSI; determine a total number of non-zero coefficients based on the codeword, where the codeword identifies the total number of non-zero coefficients, and where the total number of non-zero coefficients is associated with the CSI codebook over a set of transmission layers.

Abstract: Provided herein are methods of treating metabolic diseases or disorders in a subject in need thereof and methods of reducing weight in a subject in need thereof by using compounds having the structure of Formula Ia, wherein the compounds comprise a therapeutic agent having the configuration of [diacid]-[linker]-[an amylin analog], in which the amylin analog has the amino acid sequence of SEQ ID NO: 20, with a proviso that the amino acid sequence comprises one or more of the following amino acid substitutions: N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof, and the compounds have an anion:cation molar ratio of from about 1:1 to about 1:3.

Abstract: Provided herein are compositions or compounds comprising therapeutic proteins or peptides for treating metabolic diseases or disorders and/or for reducing weight in a subject in need thereof, and methods of using thereof.

Abstract: A delivery system includes an insertion device and an implant. The insertion device includes a body comprising a push button, a pusher wire, a backbone and a pushing mechanism. The pusher wire comprises a first end and a second end. The second end of the pusher wire is coupled to the pushing mechanism. The insertion device further includes an inserter tip comprising a needle. The inserter tip is configured to affix to the body. The implant is configured to be loaded into the insertion device. Upon depression of the push button, the pushing mechanism is activated and the pushing mechanism pushes the pusher wire into the implant and through the needle at a constant velocity and a predefined distance.

Abstract: Apparatuses, methods, and systems are disclosed for preparing CSI. One apparatus includes a processor and a memory with instructions executable by the processor to cause the apparatus to determine a total number of non-zero coefficients associated with a CSI codebook over a set of transmission layers and encode an indication of the total number of non-zero coefficients by selecting a codeword from a plurality of candidate codewords in which the selected codeword identifies the total number of non-zero coefficients. The instructions are executable by the processor to prepare CSI based on the CSI codebook and to transmit the CSI to a base station unit, where the CSI codebook includes a plurality of precoding matrices, and where the CSI includes the selected codeword.

Abstract: Provided herein are compounds having the structure of Formula Ia, wherein the compounds comprise a therapeutic agent having the configuration of [diacid]-[linker]-[an amylin analog], in which the amylin analog has the amino acid sequence of SEQ ID NO: 20, with a proviso that the amino acid sequence comprises one or more of the following amino acid substitutions: N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof, and the compounds have an anion: cation molar ratio of from about 1:1 to about 1:3, and methods of using thereof for the treatment of metabolic diseases or disorders, including type 1 diabetes, type 2 diabetes, obesity, overweight, and nonalcoholic steatohepatitis, and for reducing weight in a subject in need thereof.

Abstract: Provided herein are compounds having the structure of Formula I, wherein the compounds comprises a therapeutic agent having the sequence of SEQ ID NO: 35, and the compounds have an anion:cation molar ratio of from about 1:1 to about 1:7, and methods of using thereof for the treatment of metabolic diseases or disorders, including type 1 diabetes, type 2 diabetes, obesity, overweight, and nonalcoholic steatohepatitis, and for reducing weight in a subject in need thereof.

Abstract: Provided herein are compounds having the structure of Formula Ia, wherein the compounds comprise a therapeutic agent having the sequence of SEQ ID NO: 35, and the compounds have an anion:cation molar ratio of from about 1:1 to about 1:7, and methods of using thereof for the treatment of metabolic diseases or disorders, including type 1 diabetes, type 2 diabetes, obesity, overweight, and nonalcoholic steatohepatitis, and for reducing weight in a subject in need thereof.

Abstract: The present disclosure relates to media compositions and/or supplements to be added into an organoid medium, and to methods for generating apical-out organoids. Apical-out organoids exhibit an apical surface thereof facing the external environment, and an inwardly disposed basolateral surface. Apical-out organoids may be formed in organoid media comprise a basal medium and one or more of an inhibitor of notch signaling and an inhibitor of signaling through a TGF. Apical-out organoids formed in accordance with the disclosed methods or in the disclosed media may be used to assay host responses to pathogens.

Abstract: The invention relates to recombinant viral vectors for the insertion and expression of foreign genes for use in safe immunizations to protect against a variety of pathogens. The invention also relates to multivalent compositions or vaccine comprising one or more recombinant viral vectors for protection against a variety of pathogens. The present invention relates to methods of making an using said recombinant viral vectors.

Abstract: Provided herein are compositions or compounds comprising ionic liquids and therapeutic proteins or peptides, and methods of use thereof for the treatment of diseases or disorders.

Abstract: Generating a channel state information (CSI) feedback report is provided. A set of reference signals is received. A plurality of entries that are included in the CSI feedback report are computed, where the entries of the CSI feedback report include at least a set of coefficients. Each coefficient is associated with a set of indices including at least one or more of a spatial domain basis index, a frequency domain basis index, and a layer index. The plurality of entries of the CSI feedback report are arranged in an order known to both the user equipment and the network entity. The plurality of entries of the CSI feedback report are prioritized using indices corresponding to the set of indices, where a subset of the set of indices are permuted based on predefined permutations of the subset of the set of indices.

Abstract: Provided herein are compositions or compounds comprising ionic liquids and therapeutic proteins or peptides, and methods of use thereof for the treatment of diseases or disorders.

Abstract: Provided herein are compositions or compounds comprising ionic liquids and therapeutic proteins or peptides, and methods of use thereof for the treatment of diseases or disorders.

Abstract: Provided herein are compositions or compounds comprising ionic liquids and therapeutic proteins or peptides, and methods of use thereof for the treatment of diseases or disorders.